Successes and failures: What did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

BMC Medicine

Volumn 15, Issue 1, 2017, Pages

  Remon, Jordi ^a,b   Besse, Benjamin ^a,c   Soria, Jean Charles ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

First line; Immunotherapy; Nivolumab; Non small cell lung cancer; PD 1; PD L1; Pembrolizumab

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CARBOPLATIN; DURVALUMAB; GEMCITABINE; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; PLATINUM DERIVATIVE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANIBODY; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ALK GENE; ANTIGEN EXPRESSION; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; EGFR GENE; FOOD AND DRUG ADMINISTRATION; GENE; HAZARD RATIO; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; SURVIVAL TIME; TREATMENT DURATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOTHERAPY; LUNG NEOPLASMS; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS;

EID: 85014878389     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-017-0819-3     Document Type: Short Survey

References (47)

1. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5:2892-911.
2. Dearden S, Stevens J, Wu Y-L, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24:2371-6. doi: 10.1093/annonc/mdt205.
3. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, Simo GV, Vansteenkiste J, Peters S, ESMO Guidelines Committee. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v1-v27. doi: 10.1093/annonc/mdw326.
4. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450-61. doi: 10.1016/j.ccell.2015.03.001.
5. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-64. doi: 10.1038/nrc3239.
6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74. doi: 10.1016/j.cell.2011.02.013.
7. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064-74. doi: 10.1158/1078-0432.CCR-13-3271.
8. Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6:e1792. doi: 10.1038/cddis.2015.162.
9. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-35. doi: 10.1056/NEJMoa1504627.
10. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-39. doi: 10.1056/NEJMoa1507643.
11. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540-50. doi: 10.1016/S0140-6736(15)01281-7.
12. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, OAK Study Group, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-65. doi: 10.1016/S0140-6736(16)32517-X.
13. Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, Belani CP, et al. Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer. J Thorac Oncol. 2016;11:OA03. 06.
14. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33:2004-12. doi: 10.1200/JCO.2014.58.3708.
15. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fülöp A, KEYNOTE-024 Investigators, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-33. doi: 10.1056/NEJMoa1606774.
16. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124-8. doi: 10.1126/science.aaa1348.
17. Brahmer J, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Health-related quality of life for pembrolizumab vs chemotherapy in advanced NSCLC with PD-L1 TPS ≥50%: data from KEYNOTE-024. J Clin Oncol. 2016;34:Abstr 7153.
18. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-51. doi: 10.1200/JCO.2007.15.0375.
19. Fukuoka M, Wu Y-L, Thongprasert S, Sunpaweravong P, Leong S-S, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866-74. doi: 10.1200/JCO.2010.33.4235.
20. Solomon BJ, Mok T, Kim D-W, Wu Y-L, Nakagawa K, Mekhail T, PROFILE 1014 Investigators, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167-77. doi: 10.1056/NEJMoa1408440.
21. Miyauchi E, Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, North-East Japan Study Group, et al. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Jpn J Clin Oncol. 2015;45:670-6. doi: 10.1093/jjco/hyv054.
22. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Spanish Lung Cancer Group, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958-67. doi: 10.1056/NEJMoa0904554.
23. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17:976-83. doi: 10.1016/S1470-2045(16)30053-5.
24. Moro-Sibilot D, Smit E, de Castro CJ, Lesniewski-Kmak K, Aerts JG, Villatoro R, et al. Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: analysis from the European FRAME study. Lung Cancer. 2015;90:427-32. doi: 10.1016/j.lungcan.2015.11.011.
25. Peters S, Bexelius C, Munk V, Leighl N. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev. 2016;45:139-62. doi: 10.1016/j.ctrv.2016.03.009.
26. Franceschini D, Franzese C, Navarria P, Ascolese AM, De Rose F, Del Vecchio M, Santoro A, Scorsetti M. Radiotherapy and immunotherapy: can this combination change the prognosis of patients with melanoma brain metastases? Cancer Treat Rev. 2016;50:1-8. doi: 10.1016/j.ctrv.2016.08.003.
27. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, KEYNOTE-001 Investigators, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-28. doi: 10.1056/NEJMoa1501824.
28. Salloum RG, Smith TJ, Jensen GA, Lafata JE. Using claims-based measures to predict performance status score in patients with lung cancer. Cancer. 2011;117:1038-48. doi: 10.1002/cncr.25677.
29. Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Biomarkers France Contributors, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387:1415-26. doi: 10.1016/S0140-6736(16)00004-0.
30. Khan SA, Pruitt SL, Xuan L, Gerber DE. Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options. JAMA Oncol. 2016;2:1507-8. doi: 10.1001/jamaoncol.2016.2238.
31. Socinski M, Creelan B, Horn L, Reck M, Paz-Ares L, Steins M, et al. NSCLC, metastatic CheckMate 026: a phase 3 trial of nivolumab vs investigator's choice of platinum-based doublet chemotherapy as first-line therapy for stage IV/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC. Ann Oncol. 2016;27:LBA7_PR. doi: 10.1093/annonc/mdw435.39.
32. Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2016 (epub ahead of print). doi: 10.1158/1078-0432.CCR-16-1741.
33. Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34:2980-7. doi: 10.1200/JCO.2016.66.9929.
34. Champiat S, Ferté C, Lebel-Binay S, Eggermont A, Soria JC. Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy. Oncoimmunol. 2014;3:e27817. doi: 10.4161/onci.27817.
35. Leroi N, Lallemand F, Coucke P, Noel A, Martinive P. Impacts of ionizing radiation on the different compartments of the tumor microenvironment. Front Pharmacol. 2016;7:78. doi: 10.3389/fphar.2016.00078.
36. Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 2010;102:115-23. doi: 10.1038/sj.bjc.6605465.
37. Peng J, Hamanishi J, Matsumura N, Abiko K, Murat K, Baba T, et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-ΚB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res. 2015;75:5034-45. doi: 10.1158/0008-5472.CAN-14-3098.
38. Zhang P, Ma Y, Lv C, Huang M, Li M, Dong B, et al. The up-regulation of PD-L1 promotes the resistant response in non-small cell lung cancer patients with neo-adjuvant chemotherapy. Cancer Sci. 2016;107:1563-71. doi: 10.1111/cas.13072.
39. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, KEYNOTE-021 Investigators, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17:1497-508. doi: 10.1016/S1470-2045(16)30498-3.
40. Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31:4349-57.
41. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107:4275-80. doi: 10.1073/pnas.0915174107.
42. Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18:31-41. doi: 10.1016/S1470-2045(16)30624-6.
43. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665-73. doi: 10.1016/S0140-6736(14)60845-X.
44. Reck M, Kaiser R, Mellemgaard A, Douillard J-Y, Orlov S, Krzakowski M, LUME-Lung 1 Study Group, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15:143-55. doi: 10.1016/S1470-2045(13)70586-2.
45. Cherny N, Sullivan R, Torode J, Saar M, Eniu A. ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Ann Oncol. 2016;27:1423-43. doi: 10.1093/annonc/mdw213.
46. Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EGE, Piccart MJ. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European society for medical oncology magnitude of clinical benefit scale (ESMO-MCBS). Ann Oncol. 2015;26:1547-73. doi: 10.1093/annonc/mdv249.
47. Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, et al. ESMO - magnitude of clinical benefit scale V.1.0 questions and answers. ESMO Open. 2016;1:e000100. doi: 10.1136/esmoopen-2016-000100.